INTRODUCTION
Irinotecan (Camptosar®, CPT-11), a topoisomerase I inhibitor, is a standard cytotoxic agent used for the treatment of advanced metastatic colorectal cancer. Despite its clinical efficacy, irinotecan has two major dose-limiting toxicities-myelosuppression and diarrhea-that occur with unpredictable severity (Saltz et al., 2000; Rothenberg et al., 2001 ). Irinotecan has a narrow therapeutic range, and adverse effects may limit the dose that can be safely administered, and subsequently compromise tumour response and clinical outcome. A greater knowledge of human genetic variations pertaining to these variable outcomes following irinotecan treatment may allow an individualized approach to therapy.
The interindividual variability of irinotecan dose/toxicity and tumour response has been attributed mainly to inherited genetic variations in UGT1A1 gene, which encodes UDP-glucuronosyl transferase (UGT) 1A1, a key enzyme in irinotecan metabolism. The human UGT1A locus is defined by 13 first exons, which are alternatively spliced to four common exons, leading to mRNA isoforms, of which nine conduct to functionally active enzymes. Indeed, following intravenous administration, irinotecan is converted in vivo to the highly potent active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterase-mediated hydrolysis (Kawato et al., 1991; Kojima et al., 1993) . SN-38 is conjugated with glucuronic acid by hepatic and extrahepatic UGTs to form inactive SN-38-glucuronide. Several studies have identified specific inherited differences in irinotecan glucuronidation capacity that influence toxicity (Ando et al., 2000; Iyer et al., 2002; Innocenti et al., 2004; Marcuello et al., 2004; Mathijssen et al., 2004; Carlini et al., 2005; de Jong et al., 2006; McLeod et al., 2006; Toffoli et al., 2006 ). An increased number of dinucleotide repeats in the atypical TATA-box region of UGT1A1 promoter (UGT1A1*28 allele) leads to a decreased rate of transcription initiation/expression of UGT1A1 (Beutler et al., 1998) . Several studies suggest that patients homozygous for UGT1A1*28 are more likely to develop dose dependent severe neutropenia compared to individuals with the reference genotype This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on February 5, 2013 as DOI: 10.1124 at ASPET Journals on October 19, 2017 jpet.aspetjournals.org Downloaded from (*1/*1) (Iyer et al., 2002; Innocenti et al., 2004; Marcuello et al., 2004; Carlini et al., 2005; Soepenberg et al., 2005; Toffoli et al., 2006; Hoskins et al., 2007) . Other genetic variations also linked to toxicity, such as the non-synonymous coding variant G71R (UGT1A1*6 allele), are particularly prevalent in Asians (frequency of 0.13-0.25) and lead to variable enzyme activity (Jada et al., 2007) . Additionally, there are few data regarding the relationship with diarrhea, the other major adverse effect (Carlini et al., 2005; Toffoli et al., 2006) . Thus, the clinical value of UGT1A1 polymorphisms as predictors of irinotecan-associated toxicity has limitations, supporting the need for additional studies before implementation of individualized irinotecan dosing.
Along with UGT1A1 enzyme, several studies have revealed the importance of UGT1A9 in the hepatic conjugation of SN-38, whereas UGT1A7 is predominantly involved in its extrahepatic metabolism (Hanioka et al., 2001; Gagne et al., 2002) . UGT1A6 has catalytic activity toward SN-38 in vitro (Gagne et al., 2002) , but the effect on irinotecan metabolism is relatively undefined in vivo. Recent observations suggested that a combined signature of the haplotypes of UGT1A1, UGT1A6, UGT1A7 and UGT1A9 might provide more precise information about irinotecan pharmacokinetics, pharmacodynamics, and time to progression defined as the interval between the first drug (FOLFIRI) administration and the date of first disease progression (documented by computed tomography scans of measurable lesions) or last follow-up (Cecchin et al., 2009) . Therefore, clinical outcome is likely the result of complex interplay, at least in part, between key genomic variations in UGTs metabolic detoxification pathways.
Here, a cohort of 167 Canadian patients treated with FOLFIRI-based regimens for metastatic colorectal cancer was prospectively studied for hematological and gastrointestinal (GI) toxicities in relation to germline polymorphisms in the major UGT1A gene. A first series of analyses focused on specific UGT1A variants including the UGT1A1*28 and their haplotypes previously associated with severe neutropenia by Cecchin et al. 2009 (Cecchin et al., 2009 (Cecchin et al., 2009) . We also tested the inclusion of a 3'UTR variant common to all UGT1As and defined a novel haplotype associated with the absence of neutropenia (HIa) in the combined analysis of Canadian and Italian patients. In a second series of investigations, we tested a broader range of variations across the UGT1A gene (n=21) genotyped in Canadian patients, with the aim to identify a better combination of UGT1A markers (haplotypes) associated with the presence and the absence of neutropenia. We report 4-marker haplotypes (SNPs in UGTs 1A9/1A7/1A6/3'UTR) that may help to refine prediction of hematological toxicities, and ultimately improving dosing strategies.
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PATIENTS AND METHODS
Study design and patients
This multi-institution prospective study involved patient recruitment from 2003 to 2012 at three medical centres in eastern Canada: Hotel-Dieu de Québec in Québec City, Quebec; Hotel-Dieu de Lévis in Lévis, Québec; and The Ottawa Hospital in Ottawa, Ontario. The ethics committee of each participating institution approved the study protocol, and all patients signed a written informed consent before entering the study. Eligibility criteria included patients (18-90 years old) initiating their first irinotecanbased chemotherapy with a histologically confirmed metastatic colorectal cancer, a life expectancy of at least 3 months and a good performance status (ECOG ≤ 2). The Table 1 and duration of response were assessed by RECIST criteria. Patients were considered evaluable for response if they had at least four doses of chemotherapy.
Toxicity assessment. Toxicity was evaluated prospectively and according to NCI-CTCAE v3.0 criteria.
The toxicity end points consisted of both GI and hematological toxicities, and were analyzed separately.
For GI toxicities, all patients completed a daily report of GI toxicities during the first 14 days of each cycle to record the incidence and severity of nausea, vomiting and diarrhea. For hematological toxicities, laboratory parameters were collected before each cycle of chemotherapy and/or when the treatment was delayed. The most severe toxicity reported was used for data analysis. GI toxicity was evaluable for all patients except for one who died before toxicity assessment, and another one that did not fill out the GI toxicity diary, while hematological toxicity was evaluable for 166 out of 167 patients. For the Italian cohort, details on eligibility, modalities of treatment, data collection and definitions have been published previously (Toffoli et al., 2006; Cecchin et al., 2009 ).
Genotyping
Polymorphisms included in this study and their amplification strategies including primer sequences are described in the Supplementary Materials section (Supplemental Tables 1 and 2 
Data analyses and statistics
Deviations from the Hardy-Weinberg equilibrium of allele and genotype frequencies for the various genetic variations were assessed by Fisher's exact test. Haplotypes were inferred using the Phase v2.1.1
program. Pairwise linkage disequilibrium (LD) was determined with HAPLOVIEW 3.32
(www.broad.mit.edu/mpg/haploview). Pairwise LD between polymorphisms was estimated by a loglinear model, and the extent of disequilibrium was expressed in terms of D', which is the ratio of the unstandardized coefficient to its maximal/minimal value. The possibility of genetic association was examined by testing the null hypothesis using two-tailed Fisher's exact test and was considered statistically significant for p 
RESULTS
Patient characteristics for the Canadian cohort are summarized in Table 1 . Rates of grade 3-4 hematological and GI toxicities prospectively evaluated were in keeping with previous reports (Schulz et al., 2009 ) (Supplemental Table 3 ). We studied 21 SNPs of the UGT1A gene genotyped in the cohort of 167 Canadian patients in relation to hematological and GI related toxicities. The observed allele frequency for selected SNP was in agreement with previous analyses and all of the SNP markers under study are in Hardy-Weinberg equilibrium, except for rs10929302 (p=0.01) (Supplemental Table 2 We initially tested previously reported haplotypes of the UGT1A locus named according to Cecchin et al. (Cecchin et al., 2009) (G/A), most of which are known to impair gene expression or function (Bosma et al., 1995; Beutler et al., 1998) . Odds ratios (ORs) and p-values for association with hematological toxicities are indicated in 
DISCUSSION
Irinotecan combination chemotherapy causes severe and unpredictable hematological and GI toxicities in a substantial percentage of patients (Negoro et al., 1991; Rothenberg et al., 1993; Rougier et al., 1998; Saltz et al., 2000; Rothenberg et al., 2001; Vanhoefer et al., 2001; Fuchs et al., 2003) . Despite several published studies on genetic markers that help predict irinotecan-associated severe neutropenia (reviewed in (Hoskins et al., 2007) ), much work is still required to optimize individualized treatment.
Hence, better molecular markers to identify patients at risk complications, including severe diarrhea as well as to predict clinical response would be helpful to patients and medical oncologists. Currently, pharmacogenetic data suggests that UGT1A1*28/*28 genotype confers the highest risk of severe neutropenia due to increase exposure to SN-38 (Ando et al., 2000; Iyer et al., 2002; Innocenti et al., 2004; Marcuello et al., 2004; Mathijssen et al., 2004; Rouits et al., 2004; de Jong et al., 2006; Massacesi et al., 2006; McLeod et al., 2006; Pillot et al., 2006; Toffoli et al., 2006; Cote et al., 2007; Kweekel et al., 2008; Ruzzo et al., 2008) , (Hoskins et al., 2007; Glimelius et al., 2011) . Our current study confirms that this genotype is associated with an increased risk of severe neutropenia but in univariate analyses only, whereas a more comprehensive analysis of variations at the UGT1A locus suggests that other markers in the central region of the gene and in the 3'UTR region might better predict this toxicity.
As previously reported, polymorphisms at the UGT1A locus exhibit strong LD (Kohle et al., 2003; Peters et al., 2003; Menard et al., 2009 ). There has been sporadic conflicting information on the role of functional variants in the UGT1A1 promoter and coding regions and other UGT1A genes involved in irinotecan metabolism (Schulz et al., 2009 ). However, considering that UGT1A1*28 is a well-accepted predictor of severe neutropenia and that strong LD is observed between several functional genetic variations at the UGT1A locus in diverse populations, it is thus not surprising to find an association between severe neutropenia and other common deleterious variations in UGT1A genes encoding SN-38-This article has not been copyedited and formatted. The final version may differ from this version. (Iyer et al., 1998; Ciotti et al., 1999; Hanioka et al., 2001; Gagne et al., 2002) .
Several UGT1A variations were individually associated with severe neutropenia, and their presence is inferred in the haplotype HII defined by a 5-marker haplotype across UGT1A first exons previously reported by Cecchin and collaborators, and include the UGT1A1*28 allele (Figure 2) . We further described a protective UGT1A haplotype allele (HIa) defined by the reference sequence for these 5-markers, but also a variation in the 3'UTR region of the UGT1A gene common to all UGT1A-derived enzymes. Individuals with this haplotype have less chance to experience severe neutropenia (by 2-fold) and therefore could potentially tolerate irinotecan with less hematological toxicity. Indeed, it has also been hypothesized that higher irinotecan doses can be safely administered to patients homozygous for the reference genotype UGT1A1*1/*1 owing to their relatively good tolerance of this drug (Schulz et al., 2009) . Only the UGT1A HIa haplotype was associated with a reduced incidence of neutropenia, indicating that the simple exclusion of patients with the UGT1A1*28/*28 genotype may be insufficient to predict good tolerance to irinotecan with respect to severe neutropenia. Instead of identifying a risk haplotype and inferring that UGT1A1*28 non-carriers would be protected from severe neutropenia, the assessment of haplotype HIa seems to better identify those who have low risk of irinotecan induced neutropenia, presumably owing to the high glucuronidation activity of this allele. Indeed, this haplotype, as well as the haplotype HIb but with variation in the 3'UTR, contains UGT1A1*1, the reference UGT1A6/1A7, and UGT1A9, all of which are associated with high UGT expression and glucuronidation activity. These functional alleles may act synergistically to enhance SN-38 conjugation in the liver and extrahepatic tissues. It is thus tempting to speculate that genetic variations at the 3'-end affect gene expression. More studies are definitely needed to confirm these findings and elucidate the exact 
UGT1A.
Additional analyses reveal that other variants in the central region of the UGT1A gene, namely those located in UGT1A9 and in exons UGT1A7 and UGT1A6, are significant predictors of severe neutropenia with at least 2-fold increased risk in multivariate analyses. Some of these SNPs are only partially linked to the UGT1A1*28 allele (r 2 values between 0.028 and 0.82). Haplotype analyses with these markers and the 3'UTR variation, for a total of 4 markers located in UGT1A9, UGT1A7, UGT1A6 and 3'UTR, defines 4 common haplotypes, of which one is protective referred to as HI=ATA (OR=0.50)) and two, HII=ACG and HIII=CCG that are linked to a significantly higher risk of severe neutropenia. We further reveal a dosage effect with a higher risk in patients carrying 2 markers and highest in those with 3 markers, also carrying the reference 3'UTR allele that does not confer protection.
This set of UGT1A markers seems to improve risk prediction for severe neutropenia. Previous in vitro reports support the contribution of UGT1A9, UGT1A7 and UGT1A6 enzymes in the conjugation of SN-38 (Ciotti et al., 1999) . Despite the uncertainty of the extent of the contribution of these other enzymes to SN-38 inactivation, several studies have found an association between the UGT1A7*3 allele (p.W208R) and irinotecan-induced toxicities (Ando et al., 2002; Carlini et al., 2005; Lankisch et al., 2008) . UGT1A7 is one of the extrahepatic enzymes expressed mainly in the upper GI tract, while both UGT1A6 and UGT1A9 are both expressed in the liver and other tissues (Nakamura et al., 2008) . These UGT1A variations and the identified set of UGT1A markers should be carefully evaluated in future studies of irinotecan toxicity. The limitations of the study are its exploratory nature, the limited sample size particularly for haplotype analyses, the population studied that might be relatively genetically scarcity of functional data for some of the positive markers and a need for validation and study of additional cohorts.
In conclusion, the ultimate objective of pharmacogenetic studies is to develop tests that can be used to identify patients more likely to respond to a particular therapy and individuals that are more liable to suffer adverse reactions. In our study, we characterize UGT1A haplotypes that could potentially lead to more robust predictive tests. Additional studies that include a more comprehensive assessment of variations in UGT1A including variations in the 3'UTR region and those across the locus are warranted in irinotecan-containing dosage regimens and may help clarify the role of UGT1A in the management of irinotecan toxicity and response.
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